History is littered with promising cancer treatments that worked beautifully in mice and then fell apart in people. That sobering fact hangs over every new study like a shadow. So when researchers announced they had used vitamin B12 to sneak a drug past the blood-brain barrier and shrink glioblastoma tumors in animals, the first question is always: Will this be different?
Glioblastoma kills most patients in under 15 months. Surgery, radiation, chemotherapy — the standard arsenal buys time but rarely a cure.
The core obstacle has never been a mystery. The blood-brain barrier evolved to keep toxins out, and it does its job ruthlessly. Most cancer drugs cannot get through.
Doctors have tried drilling holes in the skull. They have tried injecting drugs directly into brain tissue.
Both carry serious risks. The new approach bypasses all that. Vitamin B12 has its own dedicated transport system into the brain.
The body needs it. So the barrier waves it through. Researchers attached a cancer-killing compound to the vitamin, and the whole package rode the B12 shuttle straight to the tumor.
In animal models, it worked. The disguised drug reached its target and started killing cancer cells.
This is not the first time scientists have tried to hijack the body’s own transport systems. Similar tricks have been attempted with glucose, with amino acids, with iron. Each had complications.
Glucose transporters are everywhere in the body, so a glucose-linked drug can hit healthy tissues hard. Iron pathways are finicky.
B12 might be different. Its brain uptake is more selective. That could mean fewer side effects.
But animal studies have a grim track record. A 2014 review in the journal PLOS ONE found that fewer than 8 percent of cancer drugs that succeeded in mice ever made it to human approval. The reasons are many.
Mouse tumors grow faster. Mouse immune systems differ.
Mouse metabolism handles drugs differently. A treatment that shrinks a mouse brain tumor can fail in humans for reasons no one predicted. The next phase will be human trials.
That takes years. Safety checks are rigorous and necessary.
The drug must be tested for toxicity, for dosing, for whether it actually reaches human brain tumors the way it reaches mouse ones. Even if it passes all that, there is the question of resistance. Glioblastoma is notoriously adaptive.
It mutates. It finds workarounds. A drug that works at first may stop working as the cancer evolves.
Still, the logic here is hard to argue with. The approach uses the body’s own plumbing.
No surgery. No risky injections into the brain. If it holds up, it could change how doctors deliver drugs to the brain for a range of neurological conditions — not just cancer but maybe Alzheimer’s, Parkinson’s, multiple sclerosis.
The same barrier that blocks chemotherapy also blocks treatments for those diseases. For now, this is a tool added to the arsenal.
Not a cure. Not a breakthrough in the sense that patients will benefit tomorrow. But a genuine step forward in a fight that has frustrated oncologists for decades.
The question is whether this step leads somewhere or dead-ends like so many before it. The only way to find out is to run the trials. That is exactly what the researchers plan to do.
{“@context”: “https://schema.org”, “@type”: “NewsArticle”, “headline”: “Researchers Use Vitamin B12 to Deliver Glioblastoma Drug Past Blood-Brain Barrier”, “description”: “History is littered with promising cancer treatments that worked beautifully in mice and then fell apart in people. That sobering fact hangs over every new…”, “datePublished”: “2026-07-03T08:09:00+00:00T09:30:00+00:00”, “author”: {“@type”: “Person”, “name”: “Noah King”}, “publisher”: {“@type”: “Organization”, “name”: “InfoPulse Today”, “url”: “https://newsfeed.infopulsetoday.com/”}}
